Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 690
Filter
1.
Univ. salud ; 23(3): 248-254, sep.-dic. 2021. tab, graf
Article in Spanish | LILACS, COLNAL | ID: biblio-1341771

ABSTRACT

Resumen Introducción: Actualmente la vitamina D ha ganado importancia, por ser considerada una hormona y porque sus bajos niveles están asociados con diferentes patologías, especialmente alteraciones de la masa ósea. Objetivo: Determinar la prevalencia de bajos niveles de vitamina D en pacientes adultos con osteopenia y osteoporosis, atendidos en consulta externa de endocrinología en Popayán Cauca. Materiales y métodos: Estudio descriptivo y retrospectivo que incluyó pacientes con diagnóstico de osteopenia y osteoporosis realizado por densitometría ósea entre los años 2013 y 2016, que tenían reporte de niveles de vitamina D obtenidos por cualquier método. Se describieron características sociodemográficas, resultados de densitometría ósea, niveles vitamina D, hormona paratiroidea y calcio iónico. Resultados: Se incluyeron 300 pacientes con diagnóstico de osteopenia y osteoporosis de los cuales 211 tenían bajos niveles de vitamina D, para una prevalencia del 71,3%, el nivel promedio de 25 hidroxivitamina D fue de 24,35ng/ml. Conclusiones: La alta prevalencia de bajos niveles de vitamina D en pacientes con osteopenia y osteoporosis hace indispensable la medición de 25 hidroxivitamina D en esta población, esto con el fin de realizar una intervención terapéutica apropiada.


Abstract Introduction: Vitamin D has gained interest because it is a hormone whose low levels are associated with different pathologies such as bone mass disorders. Objective: To determine the prevalence of low levels of vitamin D in adult patients with osteopenia and osteoporosis who received care at an outpatient endocrinology clinic in Popayan, Cauca. Materials and methods: A retrospective and descriptive study that included patients diagnosed with osteopenia and osteoporosis through bone densitometry between 2013 and 2016, who also had their vitamin D levels measured by means of any laboratory method. Sociodemographic characteristics, bone densitometry results as well as vitamin D, parathormone and ionic calcium levels were described. Results: A total of 300 patients with osteopenia and osteoporosis were included in the study, of which 211 had low levels of vitamin D, representing a prevalence of 71.3%. Finally, the average level of 25-hydroxyvitamin D was 24.35 ng/ml. Conclusion: The high prevalence of low levels of vitamin D in patients with osteopenia and osteoporosis highlights the importance to measure 25-hydroxyvitamin D levels in this population in order to carry out an appropriate therapeutic intervention.


Subject(s)
Vitamin D , Bone Diseases, Metabolic , Osteoporosis , Prevalence
2.
Rev. cuba. reumatol ; 23(1): e181, tab
Article in Spanish | LILACS, CUMED | ID: biblio-1347551

ABSTRACT

El FRAX es una herramienta que mide el riesgo de fractura y cuenta con un algoritmo computarizado desarrollado por la Organización Mundial de la Salud, basado en modelos globales de cohortes de población, combinados con factores de riesgo clínico. La herramienta fue diseñada inicialmente para su aplicación por los médicos de atención primaria en mujeres posmenopáusicas y hombres sobre 50 años, aunque es válida en general entre 40-90 años. Nos propusimos desarrollar un estudio epidemiológico-clínico sobre osteoporosis y fracturas en la población general y algunos grupos especiales de riesgo que incluyen mujeres posmenopáusicas, pacientes con afecciones reumáticas, endocrinas, cáncer y con infección por VIH, así como describir el papel desempeñado por FRAX como herramienta de medición del riesgo de fractura a los 10 años de ocurrida. Asimismo, constituye un gran reto conocer e identificar los principales grupos vulnerables o de riesgo para osteoporosis y fracturas en la población cubana. Esta aplicación nos resulta prioritaria en los grupos identificados, pues permitirá conocer los riesgos de fracturas a corto y largo plazos e implementar correcta y racionalmente los estudios DXA, disponibles en el país para la toma de decisiones terapéuticas(AU)


The FRAX is a tool that has a computerized algorithm developed by the World Health Organization, based on global models of population cohorts, combined with clinical risk factors, which measures the risk of fracture. The tool was initially designed for use by primary care physicians in postmenopausal women and men over 50 years of age, although it is generally valid between 40-90 years. We set out to develop a clinical epidemiological study on osteoporosis and fractures in the general population and some special risk groups that include post-menopausal women, patients with rheumatic, endocrine, cancer and HIV-infected conditions, as well as the role played by FRAX as a measurement tool. The ten-year risk of fracture related to the importance of knowing and identifying the main vulnerable or risk groups for osteoporosis and fractures in the Cuban population constitutes a great challenge. This application is a priority for those groups previously identified as it will allow us to know the short and long-term risks of fractures and implement the correct use of DXA studies, available in the country with a rational use and therapeutic decision-making(AU)


Subject(s)
Humans , Osteoporosis , Risk Groups , Risk Factors , Fractures, Bone , Bone Diseases, Metabolic/diagnosis , Absorptiometry, Photon/methods , Epidemiologic Studies
3.
Rev. cuba. endocrinol ; 32(1): e256, 2021. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1289383

ABSTRACT

Introducción: Se ha descrito una probable asociación entre la presencia de osteopenia/osteoporosis y el riesgo incrementado de cardiopatía isquémica. Objetivo: Determinar la posible asociación entre la presencia de síndrome coronario agudo y la densidad mineral ósea disminuida, así como la relación de ambas condiciones con algunos factores de riesgo cardiovascular y variables de la esfera reproductiva en mujeres en etapa de climaterio. Método: Se realizó un estudio transversal descriptivo con 72 mujeres (34 con síndrome coronario agudo y 38 sin síndrome coronario agudo), que fueron seleccionadas de bases de datos del Instituto de Cardiología y Cirugía Cardiovascular. La densidad mineral ósea se determinó mediante absorciometría dual de rayos X en columna lumbar. Las pruebas Chi cuadrado y U de Mann Whitney permitieron evaluar la posible relación entre variables. Resultados: El 55,9 por ciento de las pacientes con síndrome coronario agudo y el 60,5 por ciento de las mujeres sin síndrome coronario agudo tenían densidad mineral ósea disminuida. En las mujeres con densidad mineral ósea disminuida (n=42): 81 por ciento presentaron obesidad abdominal, 78,6 por ciento dislipoproteinemia, 83,3 por ciento hipertensión arterial y 76,2 por ciento refirieron el antecedente familiar de cardiopatía isquémica. Conclusiones: En las mujeres en etapa de climaterio estudiadas no se demostró asociación entre la presencia de síndrome coronario agudo y la densidad mineral ósea disminuida. Tampoco existió relación entre la presencia de síndrome coronario agudo y la densidad mineral ósea disminuida con factores de riesgo cardiovascular, ni con las variables de la esfera reproductiva(AU)


Introduction: A probable association has been described between the presence of osteopenia/osteoporosis and the increased risk of ischemic heart disease. Objective: To determine the possible association between the presence of acute coronary syndrome and decreased bone mineral density, as well as the relationship of both conditions with some cardiovascular risk factors and variables of the reproductive sphere in women during the climacteric stage. Method: A descriptive and cross-sectional study was carried out with 72 women (34 with acute coronary syndrome and 38 without acute coronary syndrome), who were selected from databases of the Institute of Cardiology and Cardiovascular Surgery. Bone mineral density was determined by dual lumbar spine X-ray absorptiometry. The chi-square and Mann Whitney U tests allowed to evaluate the possible relationship between variables. Results: 55.9 percent of the patients with acute coronary syndrome and 60.5 percent of the women without acute coronary syndrome had decreased bone mineral density. Among women with decreased bone mineral density (n=42), 81 percent had abdominal obesity, 78.6 percent had dyslipoproteinemia, 83.3 percent had arterial hypertension, and 76.2 percent had a family history of ischemic heart disease. Conclusions: In the women in the climacteric stage studied, no association was shown between the presence of acute coronary syndrome and decreased bone mineral density. There was no relationship either between the presence of acute coronary syndrome and decreased bone mineral density with cardiovascular risk factors, or with variables in the reproductive sphere(AU)


Subject(s)
Humans , Female , Adult , Middle Aged , Osteoporosis/diagnosis , Bone Diseases, Metabolic/etiology , Climacteric , Heart Disease Risk Factors , Bone Density , Epidemiology, Descriptive , Cross-Sectional Studies , Dyslipidemias/pathology , Acute Coronary Syndrome/pathology
4.
Femina ; 49(1): 39-43, 20210131. ilus
Article in Portuguese | LILACS | ID: biblio-1146939

ABSTRACT

"Tríade da mulher atleta" e "deficiência relativa de energia no esporte" são afecções comuns encontradas em esportistas. Tendo como fisiopatologia a disponibilidade energética negativa, essas síndromes têm impacto negativo na saúde das atletas. Apesar de serem frequentemente discutidas entre especialistas vinculados ao mundo desportivo, ainda são pouco conhecidas entre outras especialidades. Essa revisão da literatura foi proposta com o intuito de expor o problema ao ginecologista e obstetra, considerando esses profissionais importantes aliados na prevenção e diagnóstico precoce. Da mesma maneira, a intervenção terapêutica correta minimiza os diversos prejuízos à saúde e melhora o desempenho esportivo.(AU)


"Female athlete triad" and "relative energy deficiency in sport" are conditions relatively common among women participating in sports. Its pathophysiology based on negative energy availability, these syndromes have a negative impact on the athlete's health. Although they are frequently discussed among specialists linked to the sports all over the world, a little has been known among other physicians. This literature review was proposed in order to expose the problem to the gynecologist and obstetrician, considering these professionals as important allies in prevention and early diagnosis. In the same way, the correct therapeutic intervention allows to minimizes the numerous damages to athlete's health and to improve their sports performance.(AU)


Subject(s)
Humans , Female , Female Athlete Triad Syndrome/complications , Female Athlete Triad Syndrome/physiopathology , Female Athlete Triad Syndrome/prevention & control , Osteoporosis , Bone Diseases, Metabolic , Risk Factors , Sports Nutritional Sciences , Menstruation Disturbances
5.
Article in Chinese | WPRIM | ID: wpr-879893

ABSTRACT

OBJECTIVE@#To investigate the incidence rate and risk factors for metabolic bone disease of prematurity (MBDP) in very low birth weight/extremely low birth weight (VLBW/ELBW) infants.@*METHODS@#The medical data of 61 786 neonates from multiple centers of China between September 1, 2013 and August 31, 2016 were retrospectively investigated, including 504 VLBW/ELBW preterm infants who met the inclusion criteria. Among the 504 infants, 108 infants diagnosed with MBDP were enrolled as the MBDP group and the remaining 396 infants were enrolled as the non-MBDP group. The two groups were compared in terms of general information of mothers and preterm infants, major diseases during hospitalization, nutritional support strategies, and other treatment conditions. The multivariate logistic regression analysis was used to investigate the risk factors for MBDP.@*RESULTS@#The incidence rate of MBDP was 19.4% (88/452) in VLBW preterm infants and 38.5% (20/52) in ELBW preterm infants. The incidence rate of MBDP was 21.7% in preterm infants with a gestational age of < 32 weeks and 45.5% in those with a gestational age of < 28 weeks. The univariate analysis showed that compared with the non-MBDP group, the MBDP group had significantly lower gestational age and birth weight, a significantly longer length of hospital stay, and a significantly higher incidence rate of extrauterine growth retardation (@*CONCLUSIONS@#A lower gestational age, hypocalcemia, extrauterine growth retardation at discharge, and neonatal sepsis may be associated an increased risk of MBDP in VLBW/ELBW preterm infants. It is necessary to strengthen perinatal healthcare, avoid premature delivery, improve the awareness of the prevention and treatment of MBDP among neonatal pediatricians, and adopt positive and reasonable nutrition strategies and comprehensive management measures for preterm infants.


Subject(s)
Birth Weight , Bone Diseases, Metabolic/etiology , China/epidemiology , Female , Humans , Infant , Infant, Extremely Low Birth Weight , Infant, Newborn , Infant, Premature , Infant, Very Low Birth Weight , Pregnancy , Retrospective Studies , Risk Factors
6.
Adv Rheumatol ; 61: 11, 2021. tab
Article in English | LILACS | ID: biblio-1152745

ABSTRACT

Abstract Background: Sickle cell disease (SCD) is an autosomal recessive genetic disease in which a mutation occurs in the β-globin chain gene, resulting in abnormal hemoglobin levels. In an environment with reduced oxygen concentration, red blood cells change their conformation, resulting in chronic hemolysis and consequent anemia and vaso-occlusive crises with injuries to several organs, with a significant impairment of the osteoarticular system. This study aimed to verify the chronic osteoarticular alterations and their association with clinical and laboratory characteristics of patients with SCD with a more severe phenotype (SS and Sβ0), on a steady-state fasis. Methods: Fifty-five patients were referred to a medical consultation with a specialized assessment of the locomotor system, followed by laboratory tests and radiographic examinations. Results: In total, 74.5% patients had hemoglobinopathy SS; 67.3% were female; and 78.2% were non-whites. The mean patient age was 30.5 years. Most patients (61.8%) reported up to three crises per year, with a predominance of high-intensity pain (65.5%). Radiographic alterations were present in 80% patients. A total of 140 lesions were identified, most which were located in the spine, femur, and shoulders. Most lesions were osteonecrosis and osteoarthritis and were statistically associated with the non-use of hydroxyurea. Conclusions: There was a high prevalence of chronic osteoarticular alterations, which was statistically associated only with the non-regular use of hydroxyurea.(AU)


Subject(s)
Humans , Osteoarthritis/etiology , Osteonecrosis/etiology , Bone Diseases, Metabolic/etiology , Hydroxyurea/administration & dosage , Anemia, Sickle Cell/physiopathology , Prognosis , Cross-Sectional Studies/instrumentation , Risk Factors , Hydroxyurea/adverse effects
7.
Geriatr., Gerontol. Aging (Impr.) ; 14(4): 282-289, 31-12-2020.
Article in English | LILACS | ID: biblio-1151615

ABSTRACT

OBJECTIVE: To verify associations between osteopenia/osteoporosis and vitamin D and sarcopenia in the older adult population of Florianópolis, Brazil. METHODS: A cross-sectional population-based study, with 604 older adults (60 years and over). The appendicular muscle mass index (AMMI) was used to identify sarcopenia, with cutoffs of AMMI (Kg/m2) < 7.26 kg/m2 for men and < 5.50 kg/m2 for women indicating inadequate values (sarcopenia). The independent variable osteopenia/osteoporosis was measured using bone mineral density (BMD, g/cm2): T-Scores for whole body BMD, lumbar spine BMD, and femoral neck BMD, categorized as normal (BMD > -1 SD) or osteopenia/osteoporosis (BMD < -1 SD from the mean of the young adult reference population). Fasting serum samples were collected and assayed using the microparticle chemiluminescence (CMIA)/Liaison method. Vitamin D concentrations of < 30 ng/mL were defined as hypovitaminosis. Crude and adjusted logistic regression analyses were performed. RESULTS: Osteopenia/osteoporosis in the lumbar spine and femoral neck were associated with higher odds of sarcopenia in women and men. Osteopenia/osteoporosis in the whole body was associated with sarcopenia in women only. Vitamin D was not associated with sarcopenia in either sex. CONCLUSIONS: Having osteopenia/osteoporosis was associated with sarcopenia in this older adult population.


OBJETIVO: Verificar a associação entre osteopenia/osteoporose e vitamina D com a sarcopenia na população idosa de Florianópolis. METODOLOGIA: Estudo transversal de base populacional, com 604 idosos (60 anos ou mais). O índice de massa muscular apendicular (IMMA) foi utilizado para identificar a sarcopenia, onde o IMMA (Kg/m2) ­ < 7,26 kg/m2 para homens e < 5,50 kg/m2 para mulheres ­ indicava valores inadequados (sarcopenia). A variável independente osteopenia/ osteoporose foi medida pela densidade mineral óssea (DMO, g/cm2), foram calculados os T-escores para DMO corporal total, DMO da coluna lombar e DMO do colo femoral, categorizados como normais (DMO até -1 DP) ou osteopenia/osteoporose (DMO < -1 DP da média da população adulta jovem de referência). Amostras de soro em jejum foram coletadas pelo método de quimioluminescência de micropartículas (CMIA)/Liaison. Concentrações de vitamina D < 30 ng/mL foram definidas como hipovitaminose. Foi realizada análise de regressão logística bruta e ajustada. RESULTADOS: Osteopenia/osteoporose na coluna lombar e colo do fêmur foram associadas a maiores chances de sarcopenia em mulheres e homens. Osteopenia/ osteoporose no corpo total foi associada à sarcopenia apenas em mulheres. A vitamina D não foi associada à sarcopenia em ambos os sexos. CONCLUSÕES: A presença de osteopenia/osteoporose associou-se à sarcopenia nesta população de idosos.


Subject(s)
Humans , Aged , Osteoporosis , Bone Diseases, Metabolic , Epidemiologic Factors , Sarcopenia/epidemiology , Vitamin D Deficiency , Brazil/epidemiology
8.
Rev. colomb. reumatol ; 27(4): 278-285, oct.-dic. 2020. graf
Article in Spanish | LILACS | ID: biblio-1289331

ABSTRACT

RESUMEN Se han propuesto varios estudios que sugieren que el grupo de vitaminas B posee un rol en la fisiología ósea. Se realizó una revisión bibliográfica sobre la interacción de este con la homocisteína y la relación de ambos con el metabolismo óseo y la osteoporosis. Algunos estudios han sugerido que los niveles de vitamina B, sobre todo las vitaminas B12 y B9, se han asociado a una baja densitometría ósea y a un aumentado riesgo a fractura, y que estos, a su vez, intervienen en el metabolismo de la homocisteína, por lo que su déficit puede ocasionar un estado de hiperhomocisteinemia. Publicaciones recientes proponen que la hiperhomocisteinemia se encuentra asociada a desmineralización ósea, baja calidad de masa ósea y aumento de biomarcadores de recambio óseo, dado que influye en la actividad osteoclástica y en los enlaces cruzados de colágeno. Por lo tanto, la hiperhomocisteinemia puede ser un factor que reduce la densidad y la calidad ósea. Se necesita más información para determinar el papel que tiene cada vitamina directamente en la salud ósea, o si estas solo influyen a través de las concentraciones séricas de homocisteína.


ABSTRACT Several studies have suggested a role for B-vitamins in bone physiology. A systematic review is presented on the interaction of B-vitamins with homocysteine and the relationship of both in bone metabolism and osteoporosis. The levels of vitamin-B, particularly B12 and B9, have been associated with a low bone mineral density and an increased risk of fracture. At the same time, its deficit affects the metabolism of homocysteine, which can then result in a high serum homocysteine. Recent findings have proposed that high serum homocysteine is linked to bone demineralisation, low quality of bone mass, and an increase in bone turnover biomarkers, given the influence over the osteoclastic activity and the cross-linking of collagen molecules. Therefore, high serum homocysteine could be a factor that reduces bone density and quality. More information is needed to determine whether there is a direct role of each vitamin in bone health, or if they are just influenced by homocysteine serum concentrations.


Subject(s)
Humans , Vitamin B Complex , Homocysteine , Bone and Bones , Bone Diseases, Metabolic , Biomarkers , Fractures, Bone , Metabolism
9.
Actual. osteol ; 16(2): [104]-[115], mayo.-ago. 2020. graf, tab
Article in Spanish | LILACS | ID: biblio-1129698

ABSTRACT

La fosfatasa alcalina baja o hipofosfatasemia, ya sea debida a causas genéticas (hipofosfatasia) o secundarias, presenta correlato clínico. Nuestro objetivo es estimar la prevalencia de hipofosfatasemia crónica persistente y describir sus hallazgos osteometabólicos. Se realizó una búsqueda electrónica de afiliados adultos al Hospital Italiano de Buenos Aires, entre 2013 y 2017, con al menos 2 determinaciones de fosfatasa alcalina igual a 30 UI/l o menor y ninguna mayor de 30 UI/l (rango de referencia 30-100 UI/l). Se excluyeron aquellos con causas secundarias diagnosticadas y se analizaron los correlatos clínico y bioquímico. Se detectó hipofosfatasemia crónica persistente en 78 de 105.925, 0,07% (0,06-0,09) de los afiliados. Solo uno fue excluido por tener causa secundaria. Eran 61,1% mujeres de 44 (34-56) años, fosfatasa alcalina 24 (20-27) UI/L, fosfatemia 4,1 (3,8-4,6) mg/dl. Se observaron osteoartritis, calcificaciones vasculares y fracturas, menos frecuentemente litiasis renal, calcificación del ligamento longitudinal común anterior, pérdida dental y convulsiones. El 63,6% tenían al menos una de las características clínico-radiológicas evaluadas, pero en solo 5,2% fue mencionado el diagnóstico de hipofosfatasemia en la historia clínica. La densitometría evidenció algún grado de afección (osteopenia u osteoporosis) en 76,2%. Se constataron 19 fracturas, con predominio en radio. La prevalencia de hipofosfatasemia fue similar a lo previamente reportado. El reconocimiento fue bajo; sin embargo, se observaron variadas manifestaciones músculo-esqueléticas, similares a las descriptas en la hipofosfatasia del adulto, por lo cual ­ante una hipofosfatasemia sin causa secundaria­ se sugiere considerar este diagnóstico. (AU)


Low alkaline phosphatase (ALP) or hypophosphatasemia either due to genetic (hypophosphatasia) or secondary causes, presents a clinical correlate. Our objectives are to estimate the prevalence of persistent hypophosphatasemia and to describe the clinical findings. We performed a search using the electronic medical records of the members of the Hospital Italiano de Buenos Aires health care system, between 2013 and 2017. Adult members with ≥ 2 ALP ≤ 30 IU/l, no ALP >30 IU/l (normal range 30-100 UI/l) and without diagnosed secondary causes were analyzed. Persistent hypophosphatasemia was detected in 78 of 105.925, 0.07% (0.06-0.09) of members. Only one was excluded due to a secondary cause, 61.1% were women, 44 (34-56) year-old, ALP 24 (20-27) IU/l and phosphatemia 4.1 (3.8-4.6) mg/dl. Osteoarthritis, vascular calcifications and fractures were detected, and nephrolithiasis, DISH (Diffuse idiopathic skeletal hyperostosis), tooth loss, and seizures were less frequently observed. At least one of the mentioned characteristics were present in 63.6 %, but only 5.2% had hypophosphatasemia registered in their clinical record. Densitometry showed osteopenia or osteoporosis in 76.2%. There were 19 fractures, most of them in radius. The prevalence of hypophosphatasemia was similar to what has been previously reported. Hypophosphatasemia finding in medical records was low, but far from being asymptomatic, clinical manifestations were observed. In the presence of hypophosphatasemia without a secondary cause, adult hypophosphatasia should be uspected. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Muscle, Skeletal/pathology , Hypophosphatasia/etiology , Osteoporosis/etiology , Bone Diseases, Metabolic/etiology , Bone Density , Prevalence , Cross-Sectional Studies , Hypophosphatemia/diagnosis , Hypophosphatemia/etiology , Diphosphonates/therapeutic use , Alkaline Phosphatase/deficiency , Alkaline Phosphatase/physiology , Alkaline Phosphatase/blood , Osteoporotic Fractures/etiology , Hypophosphatasia/diagnosis , Hypophosphatasia/genetics
10.
Coluna/Columna ; 19(3): 189-193, July-Sept. 2020. tab, graf
Article in English | LILACS | ID: biblio-1133571

ABSTRACT

ABSTRACT Objective To compare the use of a dynamic surgical guide (PediGuard®) and pilot hole preparation, with the use of a probe and the aid of fluoroscopy in osteoporotic or osteopenic patients undergoing pedicular fixation of the thoracic or lumbar spine. Methods One hundred and eight patients were randomized. A pilot hole was prepared with the dynamic surgical guide (PediGuard®), or with a probe with the aid of fluoroscopy. A total of 657 vertebral pedicles (120 thoracic and 180 lumbar) were included in the study. The parameters used for the comparison were: accuracy of the pedicular screw, number of fluoroscopic shots, and change in intraoperative trajectory of the perforation after detecting pedicle wall rupture. Results In the group with use of the dynamic surgical guide, malpositioning of the pedicle screws was observed in 8 (2.6%) patients and intraoperative change of perforation trajectory in 12 (4%) patients, and there were 52 fluoroscopic shots. In the group without use of the dynamic surgical guide (PediGuard®), misplacement of the pedicle screws was observed in 33 (11%) patients and intraoperative change of perforation trajectory in 47 (13.2%) patients, and there were 136 fluoroscopic shots. Conclusion The use of the dynamic surgical guide (PediGuard®) in patients with osteoporosis or osteopenia enabled more accurate placement of pedicular screws, with less change in the intraoperative course of the perforation and less intraoperative radiation. Level of Evidence II; Randomized clinical trial of lesser quality.


RESUMO Objetivo Comparar o uso de um guia cirúrgico dinâmico (PediGuard®) e o preparo de orifício piloto com uma sonda e o auxílio de fluoroscopia em pacientes com osteopenia ou osteoporose submetidos à fixação pedicular da coluna torácica ou lombar. Métodos Cento e oito pacientes foram randomizados. Um orifício piloto foi preparado com o guia cirúrgico dinâmico (PediGuard®) ou com uma sonda com auxílio de fluoroscopia. Foram incluídos no estudo 657 pedículos vertebrais (120 torácicos e 180 lombares). Os parâmetros usados para a comparação foram: acurácia da colocação do parafuso pedicular, número de disparos fluoroscópicos e mudança da trajetória intraoperatória da perfuração depois da detecção de ruptura da parede do pedículo. Resultados No grupo de pacientes em que se usou o guia cirúrgico dinâmico, observou-se mau posicionamento dos parafusos pediculares em oito (2,6%) pacientes e alteração da trajetória intraoperatória da perfuração em 12 (4%) pacientes, com 52 disparos fluoroscópicos. No grupo de pacientes em que o guia cirúrgico dinâmico (PediGuard®) não foi usado o mau posicionamento dos parafusos pediculares foi observado em 33 (11%) pacientes, a mudança intraoperatória da trajetória da perfuração foi vista em 47 (13,2%) pacientes, com 136 disparos fluoroscópicos. Conclusão O uso do guia cirúrgico dinâmico (PediGuard®) em pacientes com osteoporose ou osteopenia permitiu a colocação de parafusos pediculares com maior acurácia, com menor alteração da trajetória intraoperatória da perfuração e menor dose de radiação intraoperatória. Nível de Evidência II; Estudo clínico randomizado de menor qualidade.


RESUMEN Objetivo Comparar el uso de una guía quirúrgica dinámica (PediGuard®) y la preparación del orificio piloto con una sonda y la ayuda de fluoroscopia en pacientes con osteopenia u osteoporosis sometidos a fijación pedicular de la columna torácica o lumbar. Métodos Ciento ocho pacientes fueron asignados aleatoriamente. Se preparó un orificio piloto preparado con la guía quirúrgica dinámica (PediGuard®) o con una sonda con ayuda de fluoroscopia. Se incluyeron en el estudio 657 pedículos vertebrales (120 torácicos y 180 lumbares). Los parámetros utilizados para la comparación fueron: precisión de la colocación del tornillo pedicular, número de disparos del dispositivo de fluoroscopia y cambio en la trayectoria intraoperatoria de la perforación después de la detección de ruptura de la pared del pedículo. Resultados En el grupo de pacientes en el que se utilizó la guía quirúrgica dinámica, se observó mal posicionamiento de los tornillos pediculares en 8 (2,6%) pacientes y cambios de la trayectoria intraoperatoria de la perforación en 12 (4%) pacientes, con 52 disparos del aparato de fluoroscopia. En el grupo de pacientes en los que no se utilizó la guía quirúrgica dinámica (PediGuard®), se observó un mal posicionamiento de los tornillos pediculares en 33 (11%) pacientes, el cambio intraoperatorio de la trayectoria de perforación se observó en 47 (13,2%) pacientes, con 136 disparos fluoroscópicos. Conclusión El uso de la guía quirúrgica dinámica (PediGuard®) en pacientes con osteoporosis u osteopenia permitió la colocación de tornillos pediculares con mayor precisión, menos cambios en la trayectoria intraoperatoria de la perforación y dosis más baja de radiación intraoperatoria. Nivel de Evidencia II; Ensayo clínico aleatorizado de menor calidad.


Subject(s)
Humans , Orifice Valves , Bone Diseases, Metabolic , Bone Screws , Fluoroscopy
11.
Rev. colomb. reumatol ; 27(2): 103-111, ene.-jun. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1251642

ABSTRACT

RESUMEN La enfermedad de Paget ósea es una enfermedad metabólica del hueso de etiología no esclarecida, que se caracteriza por una fase de resorción aumentada seguida por una fase de osteoformación aberrante. Es frecuente en Europa, Norteamérica, Nueva Zelanda y Australia, pero infrecuente en Asia, Medio Oriente y África. En población colombiana hay reportes de casos. Generalmente cursa asintomática y se diagnostica incidentalmente por hallazgos radiográficos o fosfatasa alcalina elevada. El uso de bifosfonatos favorece el control del recambio óseo y permite prevenir complicaciones como las fracturas. Se presenta una serie de casos en Colombia y una revisión de la literatura.


A B S T R A C T Paget's disease of the bone is a metabolic bone disease of unknown origin, and is characterised by an increased phase of resorption, followed by an aberrant osteoformation phase. It is common in Europe, North America, New Zealand, and Australia, but infrequent in Asia, the Middle East, Africa, and in the Colombian population there are case reports. It is usually asymptomatic and is diagnosed incidentally by radiographic findings or an elevated alkaline phosphatase. The use of bisphosphonates favours the control of bone turnover and prevents complications such as fractures. A series of cases in Colombia is presented, along with a review of the literature.


Subject(s)
Humans , Middle Aged , Aged , Osteitis Deformans , Fractures, Bone , Population , Bone and Bones , Bone Diseases, Metabolic , Diphosphonates
12.
Int. j. morphol ; 38(3): 683-688, June 2020. graf
Article in English | LILACS | ID: biblio-1098307

ABSTRACT

The aim was to evaluate bone repair and gingival tissue repair in osteopenic rats. Fifteen female wistar rats were included; in all of them ovariectomy was realized to induce osteopenia; after 45 days, the animals were submitted to 2 surgical techinques 1) dental extraction of the upper central incisor with no socket preservation and 2) 5 mm cranial defect in the calvarium; 5 rats were included in the control group (G1) withput alendronate application; in the group 2 (G2) was used subcutenous alendronate (0.5 mg/kg) once for three weeks and then was realizd the both surgical techniques. In group 3 (G3), after ovariectomy was realized the both dental extraction and the calvarium defect and after that was realized the alendronate protocol. In each group, after six week was realized euthanasia and descriptive histological analysis of the surgical areas involved. In bone formation of the 5 mm cranial defect was observed with good progression in the 3 experimental models and no modification in quality of bone repair was observed. For the gingival tissue in the extraction socket, no differences were observed between G1 and G3. On other hand, in G2 a thinner and reduced gingival epithelium was found. Our results showed that alendronate was not an obstacle for bone repair; deficiencies in re-epithelialization of oral mucosa show the impact of alendronate before dental extraction.


El objetivo fue evaluar la reparación ósea y gingival en ratas con osteopenia. Quince ratas wistar hembras fueron incluidas; en todas ellas se realizo ovarectomia y fue realizada la inducción de osteopenia; después de 45 días, los animales fueron sometidos a dos técnicas quirúrgicas 1) extracciones dentales del incisivo central superior sin preservación alveolar y 2) creación de un defecto craneano de 5 mm en la calota; 5 animales fueron incluidos como grupo control (G1) sin la aplicación de alendronato; en el grupo 2 (G2) se utilizó alendronato subcutáneo (0,5 mg/kg) una vez a la semana durante 3 semanas. En el grupo 3 (G3), después de la ovarectomia se realizó la exodoncia y el defecto en el cráneo y después de ello se inicio el protocolo con alendronato. En cada grupo, después de seis semanas se realizó la eutanasia con descripción histológica de los hallazgos. En el hueso formado en el defecto craneano de 5 mm se observó una adecuada progresión de reparación en los 3 modelos experimentales y no se observó cambios importantes en el modelo de reparación. Para el tejido gingival en el sitio de extracción, no se observaron diferencias entre el grupo G1 y G3. Por otra parte, el G2 presentó un tejido mas delgado con reducción del epitelio gingival; nuestros resultados demuestran que el alendronato no fue un obstáculo en la reparación ósea; deficiencias en la re epitelización de la mucosa oral muestran el impacto del alendronato después de la exodoncia.


Subject(s)
Animals , Female , Rats , Bone Diseases, Metabolic/drug therapy , Bone Regeneration/drug effects , Alendronate/administration & dosage , Gingiva/drug effects , Osteonecrosis/drug therapy , Osteoporosis/drug therapy , Bone Diseases, Metabolic/complications , Ovariectomy , Rats, Wistar , Diphosphonates/administration & dosage
13.
Arq. bras. med. vet. zootec. (Online) ; 72(2): 633-636, Mar./Apr. 2020. ilus, graf
Article in Portuguese | ID: biblio-1128494

ABSTRACT

In order to establish a bone loss induction model in rabbits to study osteoporosis, 18 rabbits underwent ovariectomy and received methylprednisolone 1mg/kg intramuscularly on alternate days for two weeks. Immediately before ovariectomy up to 42 days after methylprednisolone administration, radiographs of the right olecranon were taken in the mediolateral position to evaluate the radiographic optical density. Before the induction of osteoporosis, rabbits presented mean values of radiographic density of 2.305mm Al and at 42 days of 1.575mm Al. The values obtained were submitted to ANOVA for repeated measures that revealed a significant drop (P< 0.001) in the density over time, proving that the induction was able to trigger bone loss of these animals. With this, it can be affirmed that the adopted protocol was enough to provoke a significant bone loss, characterizing a valid model for the study of new treatments for osteoporosis.(AU)


Subject(s)
Animals , Female , Rabbits , Osteoporosis/diagnostic imaging , Bone Regeneration , Bone Density , Bone Diseases, Metabolic/veterinary , Analysis of Variance , Models, Animal
15.
Actual. osteol ; 16(1): 47-66, Ene - abr. 2020. ilus
Article in Spanish | LILACS | ID: biblio-1140035

ABSTRACT

La "razón de ser" de nuestros huesos y esqueletos constituye un dilema centralizado en los conceptos biológicos de "estructura" y "organización", cuya solución necesitamos comprender para interpretar, diagnosticar, tratar y monitorear correctamente las osteopatías fragilizantes. Últimamente se ha reunido conocimiento suficiente para proponer aproximaciones razonables a ese objetivo. La que exponemos aquí requiere la aplicación de no menos de 6 criterios congruentes: 1) Un criterio cosmológico, que propone un origen común para todas las cosas; 2) Un criterio biológico, que explica el origen común de todos los huesos; 3) Un enfoque epistemológico, que desafía nuestra capacidad de comprensión del concepto concreto de estructura y del concepto abstracto de organización, focalizada en la noción rectora de direccionalidad espacial; 4) Una visión ecológica, que destaca la importancia del entorno mecánico de cada organismo para la adecuación de la calidad mecánica de sus huesos a las "funciones de sostén" que les adjudicamos; 5) Una correlación entre todo ese conocimiento y el necesario para optimizar nuestra aptitud para resolver los problemas clínicos implicados y 6) Una jerarquización del papel celular en el manejo de las interacciones genético-ambientales necesario para asimilar todo el problema a una simple cuestión de organización direccional de la estructura de cada hueso. Solo aplicando estos 6 criterios estaríamos en condiciones de responder a la incógnita planteada por el título. La conclusión de esta interpretación de la conducta y función de los huesos debería afectar el fundamento de la mayoría de las indicaciones farmacológicas destinadas al tratamiento de la fragilidad ósea. (AU)


The nature of the general behavior of our bones as weight-bearing structures is a matter of two biological concepts, namely, structure and organization, which are relevant to properly interpret, diagnose, treat, and monitor all boneweakening diseases. Different approaches can be proposed to trace the corresponding relationships. The one we present here involves six congruent criteria, namely, 1) a cosmological proposal of a common origin for everything; 2) a biological acknowledgement of a common origin for all bones; 3) the epistemological questioning of our understanding of the concrete concept of structure and the abstract notion of organization, focused on the lead idea of directionality; 4) the ecological insight that emphasizes the relevance of the mechanical environment of every organism to the naturally-selected adjustment of the mechanical properties of their mobile bones to act as struts or levers; 5) The clinical aspects of all the alluded associations; 6) The central role of bone cells to control the genetics/ environment interactions of any individual as needed to optimize the directionality of the structure of each of his/her bones to keep their mechanical ability within physiological limits. From our point of view, we could only solve the riddle posed by the title by addressing all of these six criteria. The striking conclusion of our analysis suggests that the structure (not the mass) of every bone would be controlled not only to take care of its mechanical ability, but also to cope with other properties which show a higher priority concerning natural selection. The matter would be that this interpretation of bone behavior and 'function' should affect the rationales for most pharmacological indications currently made to take care of bone fragility. (AU)


Subject(s)
Humans , Bone and Bones/physiology , Bone Diseases, Metabolic/diagnosis , Osteogenesis Imperfecta/diagnosis , Osteogenesis Imperfecta/therapy , Osteoporosis/diagnosis , Osteoporosis/therapy , Bone and Bones/anatomy & histology , Bone and Bones/cytology , Bone and Bones/ultrastructure , Bone Diseases, Metabolic/therapy , Epigenesis, Genetic
16.
Rev. cuba. reumatol ; 22(supl.1): e861, tab, graf
Article in Spanish | LILACS, CUMED | ID: biblio-1280389

ABSTRACT

Aunque la masa muscular y la ósea tienen igual origen embriológico, desarrollo y función, por lo que constituyen la unidad hueso-músculo, las enfermedades asociadas al envejecimiento de esta unidad se consideran de manera independiente. Sin embargo, en los últimos años se evidencia el efecto aditivo nocivo que genera la sarcopenia y la osteopenia/osteoporosis en la calidad de vida y la salud del adulto mayor y aparece el concepto de osteosarcopenia. Entre los adultos mayores se reporta la disminución progresiva de la masa y la fuerza musculares, y las caídas accidentales en el hogar (probables por fragilidad) que están entre las principales causas de muerte, lo que sugiere que un grupo de estos adultos mayores pudieran tener osteosarcopenia. Por ello se requiere desarrollar capacidades para su prevención. Se realiza una revisión narrativa para actualizar aspectos del envejecimiento de la unidad óseo-muscular, la importancia de la osteosarcopenia, sus criterios diagnósticos y opciones terapéuticas. Se estudiaron artículos completos, en idioma inglés y español, obtenidos de las bases de datos Pubmed, Scielo Regional y Google Scholar. La infiltración grasa de la unidad músculo-hueso es el evento más importante del envejecimiento, pero no existe uniformidad en el diagnóstico de la sarcopenia. Hasta el presente un aporte proteico de calcio y vitamina D, unido a ejercicios de fuerza, son las principales opciones terapéuticas. No se dispone de fármacos que actúen al unísono sobre las dos entidades que conforman la osteosarcopenia(AU)


Muscle and bone mass have the same embryological origin, development and function constituting the bone-muscle unit. However, the diseases associated with aging of this unit are considered independently. In recent years, the additive effect of sarcopenia and osteopenia / osteoporosis on the quality of life and health of the elderly has been revealed, and thus the concept of Osteosarcopenia emerged. In older adults, reporting a progressive decrease in muscle mass and strength. Along with the above, accidental falls at home (by fragility?) are among its main causes of death, suggesting that a group of these aging people may have undiagnosed Osteosarcopenia. To develop capacities for its prevention the objective of this narrative revision are update aspects related to the aging of muscle. Bone unit and diagnostic criteria and therapeutic options for Osteosarcopenia. Exhaustive review of complete articles, in English and Spanish, downloaded manually and published between 2010 and 2019, obtained from the Pubmed, Scielo Regional and Google Scholar databases. the fatty infiltration of the muscle-bone unit It is the most important event of aging, there is no uniformity in the diagnosis of sarcopenia and adequate protein intake, calcium and D vitamin and strength exercises are principal therapeutic options. There are no drugs with on both entities(AU)


Subject(s)
Humans , Aged , Aged, 80 and over , Osteoporosis , Vitamin D , Bone Diseases, Metabolic , Accidental Falls/prevention & control , Aging , Exercise/physiology , Calcium/therapeutic use , Health of the Elderly , Cause of Death , Sarcopenia , Frailty/complications , Quality of Life
17.
Rev. chil. endocrinol. diabetes ; 13(4): 154-158, 2020. ilus, tab
Article in Spanish | LILACS | ID: biblio-1123621

ABSTRACT

Introducción: El hiperparatiroidismo secundario (HPTS) es una complicación de la enfermedad renal crónica terminal (ERCT). A pesar de nuevas terapias médicas como calcimiméticos, en HPTS refractarios la paratiroidectomía (PTX) continúa siendo necesaria. Una complicación frecuente en estos pacientes posterior a la PTX es el síndrome de hueso hambriento (SHH), caracterizado por una profunda y prolongada hipocalcemia asociada a hipofosfatemia, secundaria a un excesivo aumento de su captación ósea. Una complicación menos descrita, pero con consecuencias graves e incluso fatales, es la hiperkalemia. El propósito de este trabajo consiste en enfatizar el riesgo de hiperkalemia por SHH a partir de un caso clínico, señalar los mecanismos fisiopatológicos, factores de riesgo y consideraciones terapéuticas. Caso clínico: Mujer de 35 años, con ERCT de causa desconocida, HPTS refractario con PTX total e implante de glándulas en antebrazo hace 9 años. Ingresa por recurrencia de HPTS. Cintigrama MIBI SPECT/CT® evidenció implante hiperfuncionante, indicándose PTX del injerto. Exámenes preoperatorios: calcemia 8.6 mg/dL, fosfatasas alcalinas 1115 UI/L (VN <100), PTH intacta (PTHi) 3509 pg/ml y kalemia 4.8 mEq/L. Biopsia: hiperplasia paratiroidea nodular. En postoperatorio inmediato presentó hiperkalemia de 7.1 mEq/L con cambios electrocardiográficos, requiriendo hemodiálisis de urgencia. Posteriormente desarrolló hipocalcemia, hipofosfatemia e hipomagnesemia, de difícil control. Discusión: El SHH post HPTS puede coexistir con hiperkalemia postoperatoria inmediata grave, incluso fatal si no se identifica y corrige a tiempo. El mecanismo fisiopatológico aún no está bien dilucidado. Varios factores pudieran intervenir, incluyendo aumento del metabolismo celular, traumatismo tisular, fármacos anestésicos, fluidos perioperatorios y flujo de iones transmembrana. El nivel de potasio previo a la cirugía, menor edad, género masculino, tiempo entre la última hemodiálisis y la cirugía, y duración de la PTX, son factores de riesgo para hiperkalemia postoperatoria. El conocimiento de esta grave complicación permitirá estar preparado para monitorizar y eventualmente tratar.


Introduction: Secondary Hyperparathyroidism (SHPT) is a complication of End-Stage Renal Disease (ESRD). Although new medical therapies (i.e.calcimimetics,) parathyroidectomy (PTX) continues to be necessary in refractory cases. A well-known complication after PTX is an entity called Hungry Bone Syndrome (HBS), characterized by deep and prolonged hypocalcemia associated with hypophosphatemia, secondary to an excessive increase in bone formation. A less reported complication, but with severe or even fatal consequences, is hyperkalemia. The purpose of this work consists of emphasizing the risk of hyperkalemia in HBS, reporting a clinical case that points out the physiopathological mechanisms, risk factors, and therapeutic considerations. Clinical case: 35-year-old woman with ESRD of unknown cause with refractory SHPT with total PTX and forearm gland grafts nine years ago. She presented SHPT recurrency. MIBI SPECT/CT® scan showed a hyperfunctioning implant, indicating graft PTX. Preoperative tests: calcemia 8.6 mg/dL, phosphatemia 7.3 mg/dL, alkaline phosphatases 1115 UI/L (VN<100), intact PTH (iPTH) 3509 pg/ml and kalemia 4.8 mEq/L. Biopsy: parathyroid nodular hyperplasia. In the immediate postoperative period, she presented hyperkalemia at 7.1 mEq/L with electrocardiographic changes, requiring emergency hemodialysis. Later she developed hypocalcemia, hypophosphatemia, and hypomagnesemia of difficult control. Discussion: HBS post PTX can coexist with severe immediate postoperative hyperkalemia, which can be even fatal if not detected and corrected. The physiopathological mechanism is still not entirely elucidated. Various factors could interfere, including an increase in cell metabolism, tissue traumatism, anesthetic drugs, intraoperative fluids, and transmembrane ion flow. Preoperative potassium levels, younger age, male gender, the time elapsed between last hemodialysis and surgery, and duration of PTX are risk factors for post-surgical hyperkalemia. Knowing this severe complication will allow the medical team to be prepared for monitoring and eventually treating it.


Subject(s)
Humans , Female , Adult , Bone Diseases, Metabolic/etiology , Parathyroidectomy/adverse effects , Hyperkalemia/etiology , Hyperparathyroidism, Secondary/surgery , Renal Insufficiency, Chronic/complications , Hyperparathyroidism, Secondary/complications
19.
Actual. osteol ; 15(3): 180-191, Sept-Dic. 2019. ilus
Article in English | LILACS | ID: biblio-1104226

ABSTRACT

Bone metabolism disorders are characterized by an imbalance of bone resorption and formation in the bone remodeling process. Glucocorticoids that are used to treat kidney diseases exacerbate these disorders. P-selectin and galectin-3 are molecules involved in the sclerotic process in kidney, whereas bone resorption is regulated by the interaction between the nuclear factor activator kappa b receptor (RANK), its ligand (RANKL) and the RANKL decoy receptor osteoprotegerin (OPG). The aim of this study was to investigate the cellular and molecular mechanisms of disruption of bone remodeling regulation processes, reflected by intercellular mediators (RANKL, OPG, P-selectin and galectin-3) in chronic kidney disease experimental model treated with glucocorticoids. Rats were divided into four groups of 10 animals each. The first group, the control group, included intact animals. The second group consisted of rats with impaired bone remodeling resulting from chronic kidney disease (experimental group (CKD). The third group was a group of animals with impaired bone remodeling due to exposure to glucocorticoids (experimental group (GCs)). The fourth group consisted of rats with impaired bone remodeling in chronic kidney disease, followed by exposure to glucocorticoids (experimental group (CKD + GCs)). The effects of CKD and glucocorticoid were evaluated biochemically, histologically and by measuring bone density. An enzymelinked immunoassay was used to measure intercellular mediator levels in the serum. The bone density in the experimental groups was reduced compared to the control group. RANKL levels in animals of three experimental groups were higher than in intact animals. Serum levels of OPG were higher in CKD and GCs groups than in intact animals. At the same time, in the animals' blood serum of the CKD + GCs group, the levels of OPG were lower, than those in animals from the control group. The levels of galectin-3 in the serum of the experimental groups GCs and CKD + GCs were lower than in intact animals. The serum levels of galectin-3 in animals of the CKD group were higher than those in animals from the control group. The levels of P-selectin were lower in the serum of the GCs group than in intact animals. At the same time, the levels of P-selectin were higher in the CKD and CKD + GCs groups, than those in animals from the control group. In conclusion, the study of the complex system of bone remodeling regulation, which includes many factors and their interactions, may lead to the development of new methods for treating patients with chronic kidney disease in order to prevent osteoporosis in the future. (AU)


Las enfermedades metabólicas óseas se caracterizan por un desequilibrio en el proceso de remodelación ósea en los que participan mediadores tales como receptor del activador del factor nuclear- kappa- b (RANK), su ligando (RANKL) y la osteoprotegerina (OPG). Los glucocorticoides, recuentemente empleados en el tratamiento de la enfermedad renal crónica, exacerban este desequilibrio. En la enfermedad esclerótica renal, las moléculas de adhesión celular P-selectina and galectina-3 tienen un rol fundamental. El objetivo de esta trabajo fue estudiar las alteraciones en los mediadores de la remodelación ósea (RANKL, OPG, P-selectina and galectina-3) en un modelo de enfermedad renal crónica con tratamiento glucocorticoideo. Ratas Wistar hembras fueron divididos en 4 grupos: control (C); enfermedad renal crónica con afección de la remodelación ósea (ERC); animales con afección de la remodelación ósea expuestos a glucocorticoides (GC); enfermedad renal crónica con afección de la remodelación ósea tratados con glucocorticoides (ERC+GC). Los efectos de la ERC y los GC fueron evaluados bioquímicamente, histológicamente y por medición de la densidad ósea. RANKL, OPG, Pselectina and galectina-3 se cuantificaron en muestras de sangre venosa empleando enzimoinmuno análisis. En los 3 grupos experimentales la densidad ósea se evidenció reducida y los niveles séricos de RANKL elevados respecto al grupo control. Los niveles de OPG en los grupos ERC y GC fueron superiores mientras que en el grupo ERC+GC menores respecto a los animales controles. Galectina 3 plasmática en GC y ERC+GC se encontró reducida y aumentada en los animales ERC, en comparación con los animales controles. La concentración sérica de P-selectina sérica fue mayor en los grupos ERC y ERC+GC, y menor en los animales GC respecto a los niveles plasmáticos de los animales intactos. El avance del conocimiento sobre la regulación de la remodelación ósea a través de la interacción de mediadores sistémicos, en un futuro, puede conducir al desarrollo de nuevas estrategias terapéuticas para la prevención de la osteoporosis en pacientes con enfermedad renal crónica. (AU)


Subject(s)
Animals , Rats , Chronic Kidney Disease-Mineral and Bone Disorder/chemically induced , Bone Remodeling/drug effects , Kidney Diseases/physiopathology , Osteoporosis/prevention & control , Bone Diseases, Metabolic/diagnosis , Dexamethasone/administration & dosage , Bone Density/drug effects , Chloroform/therapeutic use , Rats, Wistar , P-Selectin/drug effects , P-Selectin/blood , Galectin 3/drug effects , Galectin 3/blood , RANK Ligand/drug effects , RANK Ligand/blood , Osteoprotegerin/drug effects , Osteoprotegerin/blood , Glucocorticoids/adverse effects , Glycerol/administration & dosage , Kidney Diseases/drug therapy
20.
Evid. actual. práct. ambul ; 22(2): e001112, sept. 2019.
Article in Spanish | LILACS | ID: biblio-1046678

ABSTRACT

La osteopenia, una disminución de la densidad mineral ósea de menor severidad que la osteoporosis, definida por valores de T-score entre -1,0 y -2,5 en la densitometría ósea , podría asociarse con un mayor riesgo de fracturas. Motivado por el pedido de una paciente con osteopenia que solicita a su médico algún medicamento que le ayude a disminuir su riesgo de fracturas, el autor se pregunta si los bifosfonatos podrían ser beneficiosos para las pacientes con este factor de riesgo. Luego de realizar una búsqueda bibliográfica y seleccionar la evidencia más reciente y de mejor calidad, se concluye que estos fármacos podrían ser útiles para prevenir fracturas en mujeres mayores de 65 años con elevado riesgo de fractura,independientemente del resultado de la densitometría. (AU)


Osteopenia, a minor decrease in bone mineral density, defined by T-score values between -1.0 and -2.5 in a bone densitometry, is associated with an increased risk of fractures. Moved by the request of a patient with osteopenia who asks her doctor for any medication that may help her reduce his risk of fractures, the author wonders if bisphosphonates could be beneficial for patients with this condition. After conducting a bibliographic search and selecting the most recent and best quality evidence, he concluded that these drugs could be useful to prevent fractures in women older than 65 years with ahigh risk of fracture, regardless of densitometry results. (AU)


Subject(s)
Humans , Female , Aged , Osteoporosis/drug therapy , Bone Diseases, Metabolic/drug therapy , Diphosphonates/therapeutic use , Osteoporotic Fractures/prevention & control , Osteoporosis/etiology , Bone Diseases, Metabolic/complications , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/diagnostic imaging , Risk Factors , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL